Clinical trial NCT02889523: Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy
Official title: A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Lymphoma
DLBCL
Follicular Lymphoma
Keywords: Front line therapy
Age-adjusted International Prognostic Index (aa-IPI) >1
60 to 80 years
Lead sponsor: The Lymphoma Academic Research Organisation
Sponsor class: OTHER
Collaborators: name: Epizyme, Inc.
First posted: 2016-09-05
Enrollment: 214
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21.

Phase II of the study is designed to determine the safety and the efficacy of tazemetostat in DLBCL and FL patients :

DLBCL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab FL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab then maintenance with 6 months of tazemetostat and 24 months of Rituximab

Detailed description: Phase I:

Up to 18 patients will be recruited, using a conventional dose-escalation algorithm (3+3 patients per dose level) to identify the maximum tolerated dose (MTD) which will be deemed the RP2D. Patients will receive 8 cycles of RCHOP every 21 days and tazemetostat every day, starting on day 2 of cycle 1.

4 cohorts are defined, according to dose levels of tazemetostat: 400mg Twice a day (BID) (cohort 1, starting level), 600mg BID (cohort 2), 800mg BID (cohort 3), 200mg BID (cohort -1), depending on the observed toxicities.

Phase II:

Up to 184 patients (122 DLBCL and 62 FL) will be recruited and treated with tazemetostat at the MTD and RCHOP.

Patients will receive 6 cycles of RCHOP every 21 days and tazemetostat at the MTD every day, starting on day 2 of cyle 1, + 2 cycles of Rituximab+tazemetostat. For FL, a maintenance of tazemetostat (6 months) + rituximab (24 months) is expected

Eligibility criteria: * INCLUSION CRITERIA

  * for Cohort DLBCL ONLY

    * 1-Patients with an untreated DLBCL de novo or transformed from indolent lymphoma (CD 20 positive) with

      * Phase Ib aaIPI ≥ 2
      * Phase II: aaIPI ≥ 1ONLY
    * 2. Age between 60 and 80 years included
  * for Cohort FOLLICULAR ONLY

    * 1-High Tumor Burden (as defined by GELF criteria \> 0) frontline follicular lymphoma (FL) with high risk FLIPI 3-5
    * 2. Aged between 18 years and 80 years included
    * 11bis. Females of childbearing potential (FCBP) must agree to use one reliable form of contraception or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 12 months after discontinuation of any study treatments (R-CHOP, tazemetostat, Rituximab)
  * For both Cohorts

    * 1bis- For phase II patients: Bi-dimensionally measurable disease defined by at least one single node or tumor lesion \> 1.5 cm assessed by CT scan and/or clinical examination AND a FDG avid disease by PETscan
    * 3.ECOG performance status of 0, 1 or 2 (0 or 1 only for phase Ib)
    * 4.Signed informed consent
    * 5.Life expectancy of ≥ 90 days (3 months) before starting tazemetostat
    * 6.Adequate renal function as calculated by a creatinine clearance \> 40 mL/min by local institutional formula
    * 7. Adequate bone marrow function as defined as:

      * ANC ≥ 1500/mm3 (≥ 1.5 X 109/L)
      * Platelets ≥ 75,000/mm3 (≥ 75 X 109/L) without platelet transfusion dependency during the last 7 days
      * Hemoglobin ≥ 9 g/dL (may receive transfusion)
    * 8. Adequate liver function as defined as:

      * Total bilirubin ≤ 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert's syndrome
      * Alkaline phosphatase (in absence of bone disease), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 X ULN (or ≤ 5 X ULN if related to lymphoma involvement)
      * Patients with prior Hepatitis B and C are eligible if, for Hepatitis B detection, surface antigen is negative and/or HBV DNA is undetectable, and for Hepatitis C detection, if HCV RNA is undetectable.
    * 9. Left ventricular ejection fraction (LVEF) ≥ 50% of echocardiography or multiple gated acquisition (MUGA) scan
    * 10. Adequate tissue (surgical excision is recommended) for central pathology review and biological caracterisation (see appendix 11
    * 11. Males with partners of childbearing potential must agree to use reliable forms of contraception during 12 months after last treatment administration
    * 12. Patient covered by any social security system (for France only)
    * 13. Patient who understands and speaks one of the country official languages
* EXCLUSION CRITERIA

  * for Cohort DLBCL

    ___15-Previous treatment for B cell lymphoma, except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max)
  * for Cohort FOLLICULAR ONLY

    * 14bis. Prior therapy for lymphoma including radiotherapy except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max)
    * 17-Pregnant or lactating females
  * For both Cohorts

    * 1-Central nervous system or meningeal involvement
    * 2-Contraindication to any drug contained in the chemotherapy regimen
    * 3-Prior treatment with tazemetostat or other inhibitor of EZH2
    * 4-Patients who are undergoing active treatment for another malignancy, exceptions include: A patient who has been disease free for 2 years, or a patient with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible Patients with prior history of myeloid malignancies, including myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia(AML) or prior history of T-LBL/T-ALL are excluded whatever receiving treatment or not and whatever date of diagnosis of these pathologies
    * 5-Patients taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John's wort)
    * 6-Patients unwilling to exclude St. John's wort, Seville oranges, grapefruit juice and/or grapefruit from diet
    * 7-Major surgery within 4 weeks before first dose of study drug (minor procedures including transcutaneous biopsy, central line placement are permitted within 2 weeks of enrollment)
    * 8-Inability to take oral medication or malabsorption syndrome or any other uncontrolled gastrointestinal condition that would impare ability to take tazemetostat
    * 9-Significant cardiovascular impairment: congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of first dose of tazemetostat or ventricular arrhythmia
    * 10-Not applicable
    * 11-Active uncontrolled infection requiring systemic therapy
    * 12-Congenital immunodeficiency or known HIV (human immunodeficiency virus infection)
    * 13-Any other major illness, that in the investigator's judgement, will substantially increase the risk associated with the patient's participation in the study
    * 14-Patients who have undergone a solid organ transplant
    * 16-Treatment with any investigational drug or device within 30 days before planned first cycle of chemotherapy
    * 18-Person deprived of his/her liberty by a judicial or administrative decision
    * 19-Adult person under legal protection
    * 20-Person hospitalized without consent
    * 21-Adult person unabled to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness

Primary outcomes:
measure: Phase I : Number of Dose Limiting Toxicities
timeFrame: 1 cycle (1 cycle is 21 days)
measure: Phase I : Number of Dose Limiting Toxicities
timeFrame: 2 cycles (1 cycle is 21 days)
measure: Phase II - DLBCL Cohort : Complete Response Rate based on local assessment
timeFrame: 8 cycles (1 cycle is 21 days)
measure: Phase II - FL Cohort : Complete Response Rate based on local assessment
timeFrame: 8 cycles (1 cycle is 21 days)
Secondary outcomes:
measure: Phase I : Serum concentration of CHOP components in presence/absence of Tazemetostat
timeFrame: Change between baseline - 1 month
measure: Phase I : Serum concentration of Tazemetostat and its metabolite (EZH 6930) in presence of CHOP
timeFrame: Change between baseline - 1 month
measure: Phase I : Complete response rate (CRR) by central review using Cheson IWG criteria
timeFrame: 8 cycles (1 cycle is 21 days)
measure: Phase II - DLBCL Cohort : Number of Adverse Events (AE)/Serious Adverse Events (SAE)
timeFrame: 8 cycles (1 cycle is 21 days)
measure: Phase II - DLBCL Cohort : Complete response rate (CRR) by central review using Cheson IWG criteria
timeFrame: 8 cycles (1 cycle is 21 days)
measure: Phase II - DLBCL Cohort : Overall response rate (ORR) by central review
timeFrame: 52 weeks
measure: Phase II - DLBCL Cohort : Overall response rate (ORR) by central review
timeFrame: 104 weeks
measure: Phase II - DLBCL Cohort : progression free survival (PFS)
timeFrame: 52 weeks
measure: Phase II - DLBCL Cohort : progression free survival (PFS)
timeFrame: 104 weeks
measure: Phase II - DLBCL Cohort : duration of response (DR)
timeFrame: 52 weeks
measure: Phase II - DLBCL Cohort : duration of response (DR)
timeFrame: 104 weeks
measure: Phase II - DLBCL Cohort : overall survival (OS)
timeFrame: 52 weeks
measure: Phase II - DLBCL Cohort : overall survival (OS)
timeFrame: 104 weeks
measure: Phase II - DLBCL Cohort : best overall response (BOR)
timeFrame: 104 weeks
measure: Phase II - FL cohort : Number of AE/SAE
timeFrame: 8 cycles (1 cycle is 21 days)
measure: Phase II - FL cohort : Number of AE/SAE
timeFrame: 13 months
measure: Phase II - FL cohort : PET Complete Response Rate (PET-CRR) by central review according to Lugano 2014 criteria
timeFrame: 8 cycles (1 cycle is 21 days)
measure: Phase II - FL cohort : Complete Response Rate (CRR)
timeFrame: 31 months
measure: Phase II - FL cohort : Overall Response Rate (CRR)
timeFrame: 31 months
measure: Phase II - FL cohort : Progression Free Survival (PFS)
timeFrame: 24 months
measure: Phase II - FL cohort : Progression Free Survival (PFS)
timeFrame: 31 months
measure: Phase II - FL cohort : Event Free Survival (EFS)
timeFrame: 24 months
measure: Phase II - FL cohort : Overall Survival (OS)
timeFrame: 24 months
measure: Phase II - FL cohort : Duration of Response (DR)
timeFrame: 31 months
measure: Phase II - FL cohort : Best Overall Response
timeFrame: 31 months
Other outcomes:
Locations:
city: Bruxelles
country: Belgium
facility: Institut Jules Bordet
city: Liege
country: Belgium
facility: CHU de Liege
city: Yvoir
country: Belgium
facility: CHRU Mont Godinne
city: Argenteuil
country: France
facility: Centre Hospitalier Victor Dupouy
city: Avignon
country: France
facility: CH d'Avignon - Hôpital Henri Dufaut
city: Besançon
country: France
facility: CHU de Besançon - Hôpital Jean Minjoz
city: Bordeaux
country: France
facility: Polyclinique Bordeaux Nord Aquitaine
city: Chambéry
country: France
facility: CH de Chambéry
city: Clermont-Ferrand
country: France
facility: CHU d'Estaing
city: Creteil
country: France
facility: APHP - Hopital Henri Mondor
city: Dijon
country: France
facility: CHU de Dijon
city: Grenoble
country: France
facility: CHU Grenoble
city: La Roche sur Yon
country: France
facility: CH Départemental de Vendée
city: Lille Cedex
country: France
facility: CHRU Lille - Hôpital Claude Huriez
city: Limoges
country: France
facility: Chu de Limoges - Hopital Dupuytren
city: Lyon
country: France
facility: Centre Leon Berard
city: Marseille
country: France
facility: Institut Paoli Calmette
city: Montpellier
country: France
facility: CHU de Montpellier - Hôpital Saint-Eloi
city: Nantes
country: France
facility: CHU de Nantes - Hôtel Dieu
city: Paris Cedex 10
country: France
facility: APHP - Hôpital Saint Louis
city: Paris
country: France
facility: APHP - Hôpital de la Pitié Salpetrière
city: Perpignan
country: France
facility: CH de Perpigan
city: Pierre-Bénite Cedex
country: France
facility: CHU Lyon Sud
city: Poitiers
country: France
facility: Chu de Poitiers - Hopital de Miletrie
city: Rennes
country: France
facility: CHU de Rennes - Hôpital Pontchaillou
city: Rouen
country: France
facility: Centre Henri Becquerel
city: Saint Cloud
country: France
facility: Centre Rene Hugenin
city: Saint Priest en Jarez
country: France
facility: Institut de cancérologie de la Loire
city: Strasbourg
country: France
facility: CHRU de Strasbourg
city: Toulouse
country: France
facility: Institut Universitaire du Cancer de Toulouse - Oncopole
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
affiliation: Institut Gustave Roussy Cancer Campus Grand Paris
name: Vincent Ribrag, MD
role: STUDY_CHAIR
affiliation: Institut Gustave Roussy Cancer Campus Grand Paris
name: Clémentine Sarkozy, MD
role: STUDY_CHAIR
affiliation: Centre Régional Hospitalier de Lille
name: Franck Morshhauser, Pr
role: STUDY_CHAIR
affiliation: IUCT Oncopole de Toulouse
name: Loic Ysebaert, MD
role: STUDY_CHAIR
References:
citation: Sarkozy C, Morschhauser F, Dubois S, Molina T, Michot JM, Cullieres-Dartigues P, Suttle B, Karlin L, Le Gouill S, Picquenot JM, Dubois R, Tilly H, Herbaux C, Jardin F, Salles G, Ribrag V. A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features. Clin Cancer Res. 2020 Jul 1;26(13):3145-3153. doi: 10.1158/1078-0432.CCR-19-3741. Epub 2020 Mar 2.